(Q34777926)

25196020

4 August 2017

title

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis (English)

1 reference

4 August 2017

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Timothy D. McHugh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Patrick Phillips

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Andrew Nunn

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Angela M Crook

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Carl M Mendel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sarah K Meredith

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Stephen R Murray

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Frances Pappas

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

REMoxTB Consortium

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

7 September 2014

1 reference

25196020

4 August 2017

number of pages

11

1 reference

The New England Journal of Medicine

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1577-1587

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study

1 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Tuberculosis drug development: progress, challenges, and the road ahead

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Outpatient gatifloxacin therapy and dysglycemia in older adults

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Fluoroquinolone-associated tendinopathy: a critical review of the literature

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Activity of moxifloxacin against mycobacteria

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Penetration of moxifloxacin into peripheral compartments in humans.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Timing of relapse in short-course chemotherapy trials for tuberculosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4277680

Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis

9 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25196020

12 December 2020

inferred from PubMed ID database lookup

Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25196020

12 December 2020

inferred from PubMed ID database lookup

Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25196020

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1056/NEJMOA1407426

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25196020%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

25196020

1 reference